09.10.26 -- The Vanishing Middle: How Consultants And CROs Are Reshaping Clinical Trials

Once used primarily by large sponsors and concentrated in specific areas, functional service providers (FSPs) have evolved alongside the growing complexity and costs of clinical research.

Smaller biotechs are rethinking CRO partnerships, valuing speed, scientific access, flexibility, and transparent pricing over scale — driven by pandemic lessons and a sharper focus on operational fit.

CGT pioneers require supply chain partnerships that mitigate trial risk and complexity. Explore how to optimize pre-trial and pre-screening activities and reduce trial cost and risk with an IRT solution.

Adopt a demand-led clinical supply strategy to reduce waste, optimize limited product supply, and accelerate patient access across global clinical trials.

Overcome clinical transition challenges with integrated services, including study design, expert regulatory support, robust recruitment, and flexible manufacturing.

Running a migraine trial? Learn how specialized neuroscience support, from PRO selection to real-time data review, can resolve common study delays and endpoint gaps.

Deepen your impact in global healthcare through thought leadership, education, conferences, and partnerships that elevate visibility, strengthen expertise, and connect you with key HEOR stakeholders.

As your product transitions from clinical phases to commercial launch, flexible, globally compliant facilities stand ready to adapt to your evolving needs.

With over three decades of expertise, particularly in oncology, CNS disorders, and rare diseases, this company fosters relationship-focused partnerships with biotech firms.

Learn how to synchronize finance and R&D with a scalable operational framework. Automate manual steps and strengthen compliance to ensure your infrastructure evolves as fast as your science.

Digital health tools are changing clinical trials fast. See how regulators and researchers are keeping evidence rigorous and trial-ready.

A first assessment of compliance on EU Clinical Trial Information System (CTIS) found fewer than half of European Phase II–IV drug trials legally required to post results fully complied on time.

A risk-based quality approach can enhance participant protection, data integrity, and development success through focused oversight, strong governance, and clear documentation.